Cystatin C testing (eGFRcys or eGFRcr‐cys) can be used to: (i) improve specificity of diagnosis of CKD in older people; and (ii) stratify the risk of cardiovascular disease, kidney failure, and death in older patients. The gene discussed is CST3; the disease is kidney failure.